Last €58.29 EUR
Change Today +1.26 / 2.22%
Volume 5.5K
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 12:11 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

medtronic inc (MDT) Snapshot

Open
€57.55
Previous Close
€57.03
Day High
€58.85
Day Low
€57.39
52 Week High
11/21/14 - €58.85
52 Week Low
02/5/14 - €38.85
Market Cap
57.3B
Average Volume 10 Days
7.2K
EPS TTM
--
Shares Outstanding
983.5M
EX-Date
10/1/14
P/E TM
--
Dividend
€1.20
Dividend Yield
1.49%
Current Stock Chart for MEDTRONIC INC (MDT)

medtronic inc (MDT) Details

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

49,247 Employees
Last Reported Date: 06/20/14
Founded in 1949

medtronic inc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic inc (MDT) Key Developments

Medtronic, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended Oct. 24, 2014; Revised Earnings Guidance for the Fiscal Year 2015

Medtronic, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended Oct. 24, 2014. For the quarter, the company reported net sales of $4,366 million against $4,194 million a year ago. Earnings before income taxes were $1,022 million against $1,116 million a year ago. Net earnings were $828 million or $0.83 diluted per share against $902 million or $0.89 diluted per share a year ago. Adjusted net earnings were $952 million or $0.96 diluted per share against $919 million or $0.91 diluted per share a year ago. Adjusted earnings before income taxes were $1,183 million against $1,140 million a year ago. On cash basis, diluted earnings per share were $1.02, an increase of 5%. Non-GAAP nominal tax rate in the second quarter was 19.5%. For the six months, the company reported net sales of $8,639 million against $8,277 million a year ago. Earnings before income taxes were $2,105 million against $2,269 million a year ago. Net earnings were $1,699 million or $1.70 diluted per share against $1,855 million or $1.83 diluted per share a year ago. Adjusted net earnings were $1,885 million or $1.89 diluted per share against $1,817 million or $1.79 diluted per share a year ago. Adjusted earnings before income taxes were $2,337 million against $2,255 million a year ago. Net cash provided by operating activities was $1,223 million against $2,019 million a year ago. Additions to property, plant, and equipment were $210 million against $196 million a year ago. The company updated its revenue growth outlook and reiterated its diluted non-GAAP earnings per share (EPS) guidance for fiscal year 2015. In fiscal year 2015, the company now expects revenue growth in the range of 4% to 5% on a constant currency basis, which is at the upper end of the company's previously stated range of 3% to 5%. For fiscal year 2015, the company continues to expect diluted non-GAAP EPS in the range of $4.00 to $4.10, which implies annual diluted non-GAAP EPS growth in the range of 7% to 10% after adjusting for the expected impact from foreign currency. The company continues to expect amortization expense to remain around $90 million per quarter. For the fiscal 2015, the company expects an adjusted non-GAAP nominal tax rate to be in the range of 18% to 20%. Full year 2015 revenue will be negatively affected by approximately $280 million to $320 million, including a negative $130 million to $150 million impact in the third quarter of 2014.

Medtronic, Inc. Announces Encouraging Data from Subgroup Analysis of Diabetes Trial

Medtronic, Inc. has announced encouraging data from a pre-specified subgroup analysis of patients with diabetes in the IN.PACT SFA trial, for an investigational medical device, Admiral drug-coated balloon. For the treatment of peripheral artery disease in leg arteries above the knee, the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. provided a consistently favorable treatment effect in patients with diabetes in a landmark study of the investigational medical device, which is under review by the FDA for approval. The IN.PACT SFA trial enrolled 331 subjects at 57 sites across Europe and the US. All study subjects were randomized to treatment with the drug-coated balloon (DCB) or percutaneous transluminal angioplasty (PTA). Key outcomes from all patients in the IN.PACT SFA Trial were: the clinically driven target lesion revascularization (CD-TLR) rates at 12 months were 2.4% for the DCB group and 20.6% for the PTA group.

Medtronic, Inc. Announces Cardiac Resynchronization Therapy

Medtronic, Inc. announced new data supporting the clinical and economic value of its cardiac resynchronization therapy (CRT) devices for the treatment of heart failure, including a significant reduction in all-cause 30-day readmissions after heart failure hospitalizations. Additionally, heart failure patients who benefited early from CRT lived longer and consumed fewer hospital resources than patients who did not experience early benefit from the therapy. These new data were featured in separate presentations at the American Heart Association's Scientific Sessions 2014 in Chicago. One million people with heart failure are hospitalized each year, and 25% of them will be re-hospitalized within 30 days. Additionally, heart failure consumes intensive resources during hospitalizations and continues to cause problems following hospital stays, with six-month readmission rates of 50% 2,3,4 and mortality rates of approximately 30%. Results were measured using the Packer Clinical Composite Score (CCS), which analyzes a patient's condition as improved, unchanged or worsened using variables including death, heart failure hospitalization, a patient global assessment questionnaire, and change in symptoms as measured by New York Heart Association (NYHA) heart failure class. The pooled analysis of five Medtronic-sponsored trials (MIRACLE, MIRACLE-ICD, InSync III Marquis, PROSPECT and Adaptive CRT) identified 1,603 total patients, 1,089 of which improved, 235 remained unchanged and 279 worsened. Patients who improved or remained unchanged at six months of receiving CRT were projected to live approximately eight years compared to less than two years in the worsened group. Additionally, heart failure hospitalization rates in the first year after the six-month clinical composite score assessment were 0.13 for those who improved, 0.27 for those who were unchanged and more than three times higher (0.90) for those who worsened.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:GR €58.29 EUR +1.26

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $209.09 USD -1.11
Astellas Pharma Inc ¥1,762 JPY -18.50
Baxter International Inc $72.44 USD +0.45
Covidien PLC $98.44 USD +0.53
Stryker Corp $90.11 USD +0.46
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 25.1x
Price/Sales 4.1x
Price/Book 3.7x
Price/Cash Flow 21.9x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.